Stocktoria
FENNEC PHARMACEUTICALS INC. FENC
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2001-06-05
FENNEC PHARMACEUTICALS INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | 84.1% | 81.9% | — |
| Operating margin | -14.1% | 5.4% | -53.7% | -1276.9% | — |
| Net margin | -21.8% | -0.9% | -67.5% | -1340.5% | — |
| Return on assets | -13.8% | -1.0% | -59.7% | -88.0% | -77.4% |
| Return on equity | -27.5% | 7.4% | 138.1% | 923.1% | -110.0% |
| Debt / equity | — | -3.29× | -2.66× | -9.69× | 0.32× |
| Current ratio | 6.37 | 6.38 | 3.56 | 5.80 | 13.54 |
| Revenue growth | -6.1% | 99.9% | 1244.4% | — | — |
Source: SEC EDGAR filings · CIK 0001211583 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.